TG Therapeutics, Inc. (TGTX)

0.92 3.59
Prev Close 25.64
Open 25.53
Day Low/High 24.64 / 26.05
52 Wk Low/High 4.95 / 27.62
Volume 1.43M
Exchange NASDAQ
Shares Outstanding 126.65B
Market Cap 3.17B
P/E Ratio N/A
Div & Yield N.A. (N.A)
Profiting on Small-Cap Biotech Earnings

Profiting on Small-Cap Biotech Earnings

Don't trade the headline numbers, but cash in on those traders that do.

Are Drug Stocks What's Ailing the Market?

Are Drug Stocks What's Ailing the Market?

This move in health care takes your breath away.

Market Closes Back Where It Started

Greece provides good news, but bulk of action wasn't intraday.

More Morning Musings

It appears based on the futures that the market's rally will continue today, at least at the open. Personally, I think investors are becoming complacent given what could unfold in Greece over the next week. Everyone seems to be betting that Europe w...

3 Biotechs That Are Worth Buying

Many of these stocks are off to the races.

Cramer: Bob Dylan Was Right

The answer is blowing in the currency headwind.

A Textbook V-Shaped Bounce

Going against the bulls this time would be a very risky bet.

Momentum Is Not Dead

The chasing in certain areas was intense.

Action Was Ugly, But Healthy

If the market gaps down in the morning, watch for the dip buyers.

Stick a Fork in 2014

We get a fresh start on Friday.

Some Holiday Cheer

Biotechnology stocks see a very strong bounce.

Oil Lang Syne

The market's oil worries are long forgotton.

Forget Calling a Bottom

Just be patient and protect capital.

Strike Two

Afternoon selling plagued the market for a second straight close.

The Market Beast Refuses to Back Down

And that's making the bulls fat and sassy.

The Bulls Keep Running

And those who say it can't continue have been proven wrong.

Earnings Will Dictate

But I have doubts how easily a straight-up recovery can be pulled off.

A Step in the Right Direction

But the market still has more work to do.

Game Changer

Today's drubbing shakes things up.

TG Therapeutics CEO: Stock Volatile But Cancer Drugs on Track

TG Therapeutics CEO: Stock Volatile But Cancer Drugs on Track

Despite the recent volatility in the company's stock, TG Therapeutics cancer drugs are on track for approval and will ultimately fill a niche where old generic chemotherapies have failed.